Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients
Status:
Terminated
Trial end date:
2019-12-21
Target enrollment:
Participant gender:
Summary
A single center, open-label, study to evaluate the intra-hepatic effect of inarigivir dose
per day and three times per week on immune response and viral markers in virally suppressed
patients with chronic hepatitis B infection
Phase:
Phase 2
Details
Lead Sponsor:
F-star Therapeutics, Inc. Spring Bank Pharmaceuticals, Inc.